Hasmukh Chudgar and Family

The Chudgar family’s core logic has been to retain absolute generational control to build massive scale, proving that patience and internal accruals can outpace the frenzy of private equity. 

The Intas story begins in 1977 with patriarch Hasmukh Chudgar, a pharmacy professor and visionary pharmacist who began manufacturing drugs in a small facility in Gujarat. For decades, Hasmukh operated on a bootstrap philosophy, refusing to dilute equity early on. He meticulously brought his three sons—Binish, Nimish, and Urmish—into the fold, each adopting a specialized pillar of the empire.

Today, the brothers operate as a highly synchronized trio. Binish, the aggressive dealmaker, orchestrated the landmark $764 million acquisition of Actavis UK, transforming Intas into a global generic heavyweight. Nimish oversees the intricate web of global manufacturing and supply chains, while Urmish, a hematologist-oncologist by training, drives the company’s cutting-edge push into biopharma and biosimilars. This division of labor has allowed the Chudgars to transform a modest regional operation into India’s largest unlisted pharmaceutical behemoth, quietly preparing the third generation to inherit a global science empire.